Navigation Links
YM BioSciences Expands Phase I/II Trial for JAK Inhibitor CYT387
Date:11/18/2010

l molecule therapeutic with dual mechanisms of vascular disruption and cytotoxicity, and is currently in a Phase II trial for glioblastoma multiforme. In addition to YM's three clinical stage products, the Company has a library of more than 4,000 novel compounds identified through internal research conducted at YM BioSciences Australia which are currently being evaluated.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that our JAK1/JAK2 inhibitor CYT387 and our VDA small molecule CYT997 will generate positive efficacy and safety data in future clinical trials; that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. Except as required by applicable securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

'/>"/>
SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Ardea Biosciences to Present at Two Upcoming Investor Conferences
2. YM BioSciences Reports Fiscal First Quarter 2011 Operational and Financial Results
3. YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS
4. Regado Biosciences Awarded Three Grants from the Federal Government to Advance Research of Lead Programs
5. Sangamo BioSciences Awarded Grants for the Development of Four ZFP Therapeutic® Programs
6. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
7. X-BODY BioSciences Awarded Grant for Therapeutic Discovery Project Targeting Metastatic Tumor Stem Cells
8. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
9. Regado Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference in New York City
10. GeneLink BioSciences, Inc. Ranked 62nd Fastest Growing Company in North America on Deloittes 2010 Technology Fast 500™
11. Sangamo BioSciences Announces Third Quarter 2010 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Quincy, MA (PRWEB) September 02, 2014 ... announced today the signage of a distribution agreement ... Azelis is now distributing Myriant’s bio-succinic acid in ... Kingdom and Ireland, targeting customers in the industrial ... chemical distribution powerhouse, Azelis offers a far-reaching chemical ...
(Date:9/2/2014)... Philadelphia, PA (PRWEB) September 02, 2014 ... pioneered a new highly efficient, cost effective approach ... U.S. Patent No. 8,820,265 by the U.S. Patent ... proprietary to Opertech. , “Opertech’s taste ... is the first automated high throughput system for ...
(Date:9/2/2014)... , Sept. 2, 2014 Orexigen Therapeutics, Inc. ... U.S. Patent and Trademark Office (PTO) has issued a ... evaluated for weight loss. NB32 is a fixed-dose combination ... U.S. Patent No. 8,815,889 claims methods for treating ... The patent expires in 2024. If NB32 is approved ...
(Date:9/2/2014)... , Sept. 2, 2014  Xencor, Inc. ... company developing engineered monoclonal antibodies for the treatment ... cancer, today announced the appointment of Debra ... and the appointment of Lloyd Rowland , ... counsel. "Debra,s expertise in biologics ...
Breaking Biology Technology:Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3
... Idenix Pharmaceuticals, Inc., (NASDAQ: IDIX ) announced today ... quarter of 2011 on Monday, August 8, 2011 after U.S. ... conference call at 4:30 p.m. ET on Monday, August 8, ... quarter of 2011 and provide an update on the company,s ...
... LOS ANGELES, July 21, 2011 Genesis Biopharma, Inc. ... today announced it has named retired four-star General Merrill ... served nearly four decades in the U.S. Air Force ... 1994.  The Genesis Biopharma Board now consists of 7 ...
... 2011 Sangamo BioSciences, Inc. (Nasdaq: ... use of zinc finger nucleases (ZFNs) to produce genetically modified ... of the National Academy of Sciences (PNAS) , represents a ... tissue as a source for transplant into humans.   ...
Cached Biology Technology:Genesis Biopharma Names Former Member of the Joint Chiefs of Staff General Merrill McPeak to Board of Directors 2Sangamo BioSciences Announces Efficient Generation of Transgenic Pigs Using Zinc Finger Nuclease (ZFN) Technology 2Sangamo BioSciences Announces Efficient Generation of Transgenic Pigs Using Zinc Finger Nuclease (ZFN) Technology 3Sangamo BioSciences Announces Efficient Generation of Transgenic Pigs Using Zinc Finger Nuclease (ZFN) Technology 4
(Date:9/2/2014)... for eating anything, including each other, camel crickets are ... Carolina State University finds that non-native camel cricket species ... , "The good news is that camel crickets don,t ... says Dr. Mary Jane Epps, a postdoctoral researcher at ... the research. , The research stems from a chance ...
(Date:9/2/2014)... limestone is well known as a result of ... (for example, Archaeopteryx). Now, for the first time, ... equivalent of these outcrops - discoveries which include ... treader. , Despite the abundance of fossils in ... obtained from the Late Kimmeridgian equivalents of these ...
(Date:9/2/2014)... a hot oven, you rapidly pull your hand away. ... sensing and responding to such painful stimuli, they are ... have made a surprising discovery about the role of ... have built a structural model of the molecule. These ... may help direct new strategies to treat pain in ...
Breaking Biology News(10 mins):Researchers find Asian camel crickets now common in US homes 2Exceptionally well preserved insect fossils from the Rhône Valley 2Surprising new role for calcium in sensing pain 2Surprising new role for calcium in sensing pain 3
... such, they are relatively well studied, especially in the ... most thoroughly. First eastern US butterfly species were described ... himself, over 250 years ago. For the last ... species diversity of eastern butterflies, and every nook and ...
... A*STAR,s Institute of Molecular and Cell Biology (IMCB) have ... the pathway leading to memory and learning impairment. The ... and could be used to explain defects in the ... established knowledge could potentially facilitate exploration of strategies to ...
... plant that,s been known to drive people daffy. It,s one ... a hard-to-control weed in ponds and small lakes. But it,s ... source to produce pharmaceuticals. Now, the genome of Greater Duckweed ... as a biofuel source a big boost. In a paper ...
Cached Biology News:Two new butterfly species discovered in eastern USA 2A*STAR scientists discover protein's role in human memory and learning functions 2Pond-dwelling powerhouse's genome points to its biofuel potential 2Pond-dwelling powerhouse's genome points to its biofuel potential 3Pond-dwelling powerhouse's genome points to its biofuel potential 4
Sf21 Insect Cells (Live) in Max-XP Medium...
... cycler is a compact instrument for gene amplification ... 12 x 0.5 ml tubes, or a 48-well ... thumbwheel to adjust height and pressure to tightly ... pumps provide excellent thermal performance, and the sample ...
... The IHC Select Immunophosphatase Secondary Detection ... CHEMICON IHC Select Prediluted Primary Antibody reagents, ... the qualitative identification of antigens by light ... Immunophosphatase Secondary Detection System may also be ...
... the mitochondrial transmembrane potential is ... events that occur following induction ... Detection Kit utilizes a lipophilic ... a mitochondrial activity marker. MitoLight ...
Biology Products: